Expression of hsa-miRNA-15b, -99b, -181a and Their Relationship to Angiogenesis in Renal Cell Carcinoma.

hsa-miR-15b-5p hsa-miR-181a-5p hsa-miR-99b-5p kidney cancer microRNA prognosis

Journal

Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304

Informations de publication

Date de publication:
27 Jun 2024
Historique:
received: 27 05 2024
revised: 19 06 2024
accepted: 22 06 2024
medline: 27 7 2024
pubmed: 27 7 2024
entrez: 27 7 2024
Statut: epublish

Résumé

MicroRNAs (miRNAs) play a regulatory role in various human cancers. The roles of hsa-miR-15a-5p, hsa-miR-99b-5p, and hsa-miR-181a-5p have not been fully explored in the angiogenesis of renal cell carcinoma (RCC). The present study aimed to evaluate the expression of these miRNAs in tumorous and adjacent healthy tissues of RCC. Paired tumorous and adjacent normal kidney tissues from 20 patients were studied. The expression levels of hsa-miR-15b-5p, hsa-miR-99b-5p, and hsa-miR-181a-5p were quantified by TaqMan miRNA Assays. Putative targets were analyzed by qRT-PCR. Significant downregulation of all three miRNAs investigated was observed in tumorous samples compared to adjacent normal kidney tissues. Spearman analysis showed a negative correlation between the expression levels of miRNAs and the pathological grades of the patients. Increased expression of vascular endothelial growth factor-A (VEGF-A) and hypoxia-inducible factor-1α (HIF-1α), a tissue inhibitor of metalloproteinases-1 (TIMP-1), was observed in tumorous samples compared to adjacent normal tissues. Depletion of tissue inhibitors of metalloproteinase-2 (TIMP-2) and metalloproteinase-2 (MMP-2) was detected compared to normal adjacent tissues. The examined miRNAs might function as contributing factors to renal carcinogenesis. However, more prospective studies are warranted to evaluate the potential role of miRNAs in RCC angiogenesis.

Sections du résumé

BACKGROUND BACKGROUND
MicroRNAs (miRNAs) play a regulatory role in various human cancers. The roles of hsa-miR-15a-5p, hsa-miR-99b-5p, and hsa-miR-181a-5p have not been fully explored in the angiogenesis of renal cell carcinoma (RCC).
AIMS OBJECTIVE
The present study aimed to evaluate the expression of these miRNAs in tumorous and adjacent healthy tissues of RCC.
METHODS METHODS
Paired tumorous and adjacent normal kidney tissues from 20 patients were studied. The expression levels of hsa-miR-15b-5p, hsa-miR-99b-5p, and hsa-miR-181a-5p were quantified by TaqMan miRNA Assays. Putative targets were analyzed by qRT-PCR.
RESULTS RESULTS
Significant downregulation of all three miRNAs investigated was observed in tumorous samples compared to adjacent normal kidney tissues. Spearman analysis showed a negative correlation between the expression levels of miRNAs and the pathological grades of the patients. Increased expression of vascular endothelial growth factor-A (VEGF-A) and hypoxia-inducible factor-1α (HIF-1α), a tissue inhibitor of metalloproteinases-1 (TIMP-1), was observed in tumorous samples compared to adjacent normal tissues. Depletion of tissue inhibitors of metalloproteinase-2 (TIMP-2) and metalloproteinase-2 (MMP-2) was detected compared to normal adjacent tissues. The examined miRNAs might function as contributing factors to renal carcinogenesis. However, more prospective studies are warranted to evaluate the potential role of miRNAs in RCC angiogenesis.

Identifiants

pubmed: 39062015
pii: biomedicines12071441
doi: 10.3390/biomedicines12071441
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : TKP2021-EGA-20 (GH). Project no. TKP2021-EGA-20
ID : TKP2021-EGA-20 (GH). Project no. TKP2021-EGA-20
Organisme : GINOP-2.3.4-15-2020-00008
ID : GINOP-2.3.4-15-2020-00008
Organisme : University of Debrecen Program for Scientific Publication
ID : University of Debrecen Program for Scientific Publication
Organisme : ÚNKP-23-4-I-DE-157 New National Excellence Program of the Ministry for Culture and Innovation from the source of the National Research, Development and Innovation Fund
ID : ÚNKP-23-4-I-DE-157 New National Excellence Program of the Ministry for Culture and Innovation from the source of the National Research, Development and Innovation Fund

Auteurs

József Király (J)

Department of Biopharmacy, Faculty of Pharmacy, University of Debrecen, 4032 Debrecen, Hungary.
Doctoral School of Pharmaceutical Sciences, University of Debrecen, 4032 Debrecen, Hungary.

Erzsébet Szabó (E)

Department of Pharmacology, Faculty of Pharmacy, University of Debrecen, 4032 Debrecen, Hungary.
HUN-REN-DE Pharmamodul Research Group, Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Debrecen, 4032 Debrecen, Hungary.

Petra Fodor (P)

Department of Biopharmacy, Faculty of Pharmacy, University of Debrecen, 4032 Debrecen, Hungary.

Anna Vass (A)

Department of Biopharmacy, Faculty of Pharmacy, University of Debrecen, 4032 Debrecen, Hungary.

Mahua Choudhury (M)

Texas A&M Health Science Center, Department of Pharmaceutical Sciences, Irma Lerma Rangel School of Pharmacy, College Station, TX 77845, USA.

Rudolf Gesztelyi (R)

Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.

Csaba Szász (C)

Department of Pathology, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.

Tibor Flaskó (T)

Department of Urology, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.

Nikoletta Dobos (N)

Department of Biopharmacy, Faculty of Pharmacy, University of Debrecen, 4032 Debrecen, Hungary.

Barbara Zsebik (B)

Department of Biopharmacy, Faculty of Pharmacy, University of Debrecen, 4032 Debrecen, Hungary.

Ákos József Steli (ÁJ)

Department of Biopharmacy, Faculty of Pharmacy, University of Debrecen, 4032 Debrecen, Hungary.

Gábor Halmos (G)

Department of Biopharmacy, Faculty of Pharmacy, University of Debrecen, 4032 Debrecen, Hungary.

Zsuzsanna Szabó (Z)

Department of Biopharmacy, Faculty of Pharmacy, University of Debrecen, 4032 Debrecen, Hungary.

Classifications MeSH